Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 2003, p. 1410-1413, Vol. 41, No. 4
0095-1137/03/$08.00+0 DOI: 10.1128/JCM.41.4.1410-1413.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Laboratory of Parasitology-Mycology,1 Department of Nuclear Medicine,2 Department of Infectious Diseases, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, and Faculté de Médecine Lariboisière-Saint-Louis, Université Paris VII, Paris, France3
Received 16 August 2002/ Returned for modification 25 October 2002/ Accepted 7 January 2003
|
|
|---|
|
|
|---|
The diagnosis of microsporidiosis relies on direct visualization of spores in clinical specimens by light or fluorescent microscopy (16, 18). Electron microscopy enables Encephalitozoon genus identification (2, 20). Specific PCR is used for E. intestinalis identification (3, 4, 6, 8, 9, 12). Species identification is important as, unlike for E. bieneusi infections, treatment with albendazole is effective for E. intestinalis infections (11).
In this study, we developed a new quantitative PCR assay as a complementary tool for the assessment of E. intestinalis parasitic burden in various clinical specimens.
|
|
|---|
(ii) Dilutions of spores. Serial dilutions of spores, containing 20 to 5 x 106 spores per ml were prepared in distilled water. Similarly, serial spore dilutions were prepared by using a stool suspension as a diluent to examine the possible effect of stools on the performance of PCR. For this purpose, we used 10 g of stool from a control patient without intestinal parasitic infection, diluted the specimen in 40 ml of distilled water, and used this stool suspension to prepare spore dilutions.
(iii) DNA extraction. Two hundred microliters of each spore dilution, either in distilled water or in stool suspension, were incubated with 24 µg of lyticase (Roche Molecular Biochemicals, Meylan, France)/ml at 37°C, and then DNA was extracted by using the High Pure PCR template preparation kit (Roche Molecular Biochemicals) according to the manufacturer's instructions. Extracted DNA was resuspended in 200 µl of 10 mM Tris buffer (pH 8.5).
Clinical study. (i) Clinical specimens. Stored clinical specimens from 8 immunocompromised patients with proven E. intestinalis infection were used. Seven patients were HIV-infected and had already experienced AIDS-defining opportunistic diseases. They were all male homosexuals with CD4 cell counts below 50 per mm3. All had a history of chronic intermittent diarrhea. Fever was also documented in two patients, and cholangitis was documented in one patient. Another patient was HIV-seronegative but received chemotherapy for Hodgkin's lymphoma. His CD4 cell count was 50 per mm3. He presented with fever and bronchopulmonary symptoms but also had abdominal pain. In addition, 10 stool specimens from patients without microsporidiosis and 4 stool specimens from E. bieneusi-infected patients were tested.
(ii) Diagnosis of E. intestinalis infection. The diagnosis of E. intestinalis infection in these 8 patients relied upon demonstration of typical spores by light and Uvitex 2B microscopy (16, 18) followed by specific PCR (9). A semiquantitative assessment of parasitic burden (microscopy score) was performed by the same trained investigator (C. Sarfati) using Uvitex 2B-stained slides. A score of 0 indicated no spore seen after the observation of 200 microscopic fields at a magnification of x1,000, a score of 1 was given for rare spores (less than 1 spore per 10 microscopic fields at a magnification of x1,000), a score of 2 was given for some spores (from 1 spore per 10 fields to 2 spores per field), and a score of 3 was given for numerous spores (more than 2 spores per field).
(iii) DNA extraction from clinical specimens. For stool specimens, approximately 1 g of formed stool or 1 ml of diarrheic stool was suspended in 4 ml of distilled water and stored at -20°C until use. Two hundred microliters of each stool specimen suspension was thawed and then centrifuged at 1,500 x g for 5 min. The pellet was washed with 200 µl of phosphate-buffered saline (pH 7.2), then centrifuged at 1,500 x g for 5 min, and resuspended in 200 µl of phosphate-buffered saline. Lung biopsy samples were first incubated at 37°C for 4 h with 200 µl of tissue lysis buffer and 40 µl of proteinase K from the Roche Molecular Biochemicals High Pure PCR template preparation kit. For other types of samples (urine, sputum, bronchoalveolar lavage fluid, blood, and serum), 200 µl of the clinical specimens was directly used. Each sample was lysed for 30 min with 24 µg of lyticase/ml at 37°C, and then DNA extraction was performed by using the High Pure PCR template preparation kit according to the manufacturer's instructions. The extracted DNA was resuspended in 200 µl of 10 mM Tris buffer (pH 8.5).
Real-time quantitative PCR. Several primers and one TaqMan fluorescent probe were designed within the consensus sequence of the E. intestinalis small-subunit rRNA gene (GenBank accession no. U09929) with Primer Express software (Applied Biosystems, Foster City, Calif.). In a preliminary experiment, each was tested for E. intestinalis performance in a real-time PCR. The primer set FEI1 (5'-GCAAGGGAGGAATGGAACAGAACAG-3') and REI1 (5'-CACGTTCAGAAGCCCATTACACAGC-3') was selected, amplifying a 127-bp fragment between positions 988 and 1114. TheTaqMan fluorescent probe (5'-CGGGCGGCACGCGCACTACGATA-3' at positions 1036 to 1058) was labeled at the 5' end with 6-carboxyfluorescein and at the 3' end with 6-carboxytetramethylrhodamine. Real-time quantitative PCR was performed on an ABI Prism 7700 sequence detection system in a 50-µl volume containing 5 mM MgCl2, 1x Applied Biosystems TaqMan buffer A, 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 400 µM dUTP, 0.2 µM FEI1 primer, 0.2 µM REI1 primer, 0.4 µM TaqMan fluorescent probe, 0.5 U of Applied Biosystems AmpErase uracil DNA glycosylase, 1.25 U of Applied Biosystems AmpliTaq Gold, and 5 µl of spore-extracted standard DNA or patient sample DNA. After 2 min at 50°C and 10 min at 95°C, amplification consisted of 45 cycles of 15 s of denaturation at 95°C followed by 1 min of annealing and extension at 65°C. Results were expressed as threshold cycle (Ct) values corresponding to the cycle at which PCR enters the exponential phase, i.e., when the 6-carboxyfluorescein fluorescence exceeds 10 times the standard deviation (SD) of the mean baseline emission for cycles 3 to 15.
Each set of PCR assays comprised serial dilutions of E. intestinalis spores as external standards. Each dilution was tested in triplicate. A standard curve was established between the Ct values and the spore numbers by using the Applied Biosystems sequence detection system software, version 1.6.3. For each clinical specimen, also tested in triplicate, this standard curve was used to estimate the spore number by interpolation of the Ct value obtained by real-time PCR. Negative controls (distilled water) were included in each set of experiments.
Statistical analysis. All statistical analyses were performed with GraphPad Prism, version 3.02 for Windows (GraphPad Software, San Diego, Calif.). The means ± SDs of Ct values from dilutions of the spore suspension were calculated to assess interassay reproducibility of real-time PCR by using 5 independent experiments. A Student test was performed for comparison of Ct values for the suspension containing 20 spores per ml versus negative controls. The relation between the decimal logarithm of spore number and Ct values was assessed performing standard ordinary least-square linear regression. Slope equality for real-time PCR experiments performed with spores diluted in distilled water or in a stool suspension was assessed with an F test.
|
|
|---|
![]() View larger version (15K): [in a new window] |
FIG. 1. Correlation between Ct values (means ± SD) and number of spores per milliliter from 5 independent real-time PCR experiments on serial dilutions of E. intestinalis spores.
|
Clinical specimens. The results of real-time PCR performed on samples from patients with microsporidiosis and in uninfected controls are presented in Table 1. No amplification was observed for samples obtained from E. bieneusi-infected patients or from patients without microsporidiosis. In patients infected with E. intestinalis, parasitic burden could be determined in various types of samples taken at the same time, including tissue biopsy samples and blood. The highest parasitic burdens were noted in stools, urine, and bronchopulmonary specimens, reaching 105 to 106 spores/g or ml. In two patients, dissemination of infection was assessed by the positivity of PCR in serum or whole blood.
|
View this table: [in a new window] |
TABLE 1. E. intestinalis DNA quantitation by real-time PCR in various clinical specimens from 8 E. intestinalis-infected patients, 4 E. bieneusi-infected patients, and 10 patients without microsporidiosis
|
|
|
|---|
In this study, we described a new real-time PCR technique for quantitative detection of E. intestinalis in biological samples. Using spores obtained from tissue culture, we first showed that this technique was reliable for parasite quantitation over a wide range of spore concentrations diluted either in distilled water or in a stool suspension. In both cases, the lower threshold of detection was 20 spores/ml.
When applied to clinical samples, we showed that none of the specimens obtained from patients without microsporidiosis (n = 10) or from E. bieneusi-infected patients (n = 4) was positive by E. intestinalis real-time PCR. For patients infected with E. intestinalis, however, real-time PCR was successfully applied to several types of clinical samples, including stools, urine, sputum, tissue biopsy, blood, and serum, and allowed to estimate the level of infection in body fluids and tissues. Although only a limited number of clinical specimens was studied, our results confirmed that E. intestinalis infection predominantly involves the digestive tract, the urinary tract, and the lungs, since we found high parasite burdens in stools, urine, and sputum. Dissemination was also evidenced by the demonstration of E. intestinalis DNA in the blood of two patients, although at a lower level, as previously described (4).
In terms of routine laboratory practice, E. intestinalis real-time PCR can be performed by using any type of clinical specimen. Stool should be preferentially examined, since intestinal localization is predominant, but other samples can be considered to assess extraintestinal dissemination of infection. Real-time PCR offers the advantage of not requiring any post-PCR processing for PCR product detection, which decreases turnaround time and the risk of amplimer contamination. Additionally, the use of a simple commercially available DNA extraction kit enhances the practicability of the assay for clinical laboratories, and the entire assay, including DNA extraction, requires less than 5 h.
In conclusion, this method is a useful tool for quantitation of E. intestinalis burden in vitro and in clinical specimens. Quantitative determination of parasite burden in clinical specimens from E. intestinalis-infected patients can provide valuable information about the natural history of the infection and could also be used to assess the effect of different treatments in vivo.
We thank A. M. Deluol, from the Hôpital Saint-Antoine (Assistance Publique-Hôpitaux de Paris), who provided us with blood from an HIV-infected patient with disseminated E. intestinalis infection, L. Kitanovski from the University Children's Hospital of Ljubljana (Ljubljana, Slovenia), who provided us with pulmonary tissue from a patient with Hodgkin's lymphoma and disseminated E. intestinalis infection, and Y. J. F. Garin for helpful discussions and assistance with statistical analysis.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»